Search
Displaying 101–110 of 573 for “Retinitis pigmentosa”
-
Eye on the Cure Podcast | Episode 56: Michael Voevodsky, MBA, CEO
Eye on the CureMichael Voevodsky, MBA, CEO at MitoChem Therapeutics, talks to host Ben Shaberman about his company’s emerging, gene-agnostic treatment designed to boost mitochondrial function for preserving vision in people with retinitis pigmentosa, age-related macular degeneration, and other retinal conditions.
-
Kiora Reports Vision Restoration in Phase 1/2 Clinical Trial for Photoswitch Therapy
Research NewsThe company’s molecule is designed to restore some vision to people with ultra-low or no vision caused by advanced retinitis pigmentosa and other retinal diseases.
-
Finding the “Keys to the Kingdom”
Beacon StoriesTricia Waechter, who has retinitis pigmentosa (RP), refers to her white canes as the “keys to the kingdom.” Using a white cane has opened a whole new world for Tricia, and that is why her company, Blind Girl Designs, includes white canes on many of their apparel designs.
-
Funded Foundation Fighting Blindness Grants and Awards for Fiscal Year 2023 (July 1, 2022–June 30, 2023)
-
Eye on the Cure Podcast | Episode 49: Alex Cohen, PhD
Eye on the CureJune 30, 2023. Alex Cohen, PhD, a marketing professor with retinitis pigmentosa, talks with host Ben Shaberman about his career in the hospitality industry and launch of Accessible Pharmacy, a comprehensive pharmacy service for people with vision loss.
-
Eye on the Cure Podcast | Episode 48: Jami Kern, PhD
Eye on the CureJune 16, 2023. Jami Kern, PhD, chief clinical officer at Nacuity Pharmaceuticals, talks with host Ben Shaberman about NACA, the company’s emerging gene-agnostic therapy for Usher syndrome and retinitis pigmentosa in a Phase 2 clinical trial in Australia. Their conversation includes a discussion about oxidative stress, which NACA is designed to mitigate, and timing for the efficacy readout from the Phase 2 study.
-
The Retinal Research Community Mourns the Loss of Retinal Research Pioneer Thierry Léveillard
Beacon StoriesDr. Léveillard helped discover and develop a gene-agnostic, cone-preserving therapy for retinitis pigmentosa that’s moving into a clinical trial.
-
I Am Blind, but I Am Not the Blindness
WellnessDr. Ann Wagner is a Board-Certified Clinical Psychologist who has worked at the Minneapolis VA HCS for the past 23 years, serving veterans and their families. She works primarily on the PTSD Clinical Team providing evidenced-based assessments and interventions for PTSD and other trauma-related problems. Dr. Wagner herself is legally blind due to retinitis pigmentosa.
-
Eye on the Cure Podcast | Episode 46: Aaron Osborne, MD
Eye on the CureMay 19, 2023. Aaron Osborne, MD, chief medical officer and chief development officer at Nanoscope Therapeutics, talks about vision restoration in clinical trials of the company’s optogenetic therapy for people with advanced vision loss from retinitis pigmentosa and Stargardt disease.
-
Eye on the Cure Podcast | Episode 45: Henry Klassen, MD, PhD
Eye on the CureApril 28, 2023. Henry Klassen, MD, PhD, co-founder of jCyte and clinical researcher at UC Irvine, talks to host Ben Shaberman about jCyte’s clinical trial results and future plans for developing its cell-based therapy for preserving vision caused by retinitis pigmentosa, Usher syndrome, and related retinal conditions.
%20(13).png)
%20(8).png)
%20(7).png)
%20(5).png)
